Magenta Therapeutics Stock Forecast, Price & News

-0.16 (-2.16 %)
(As of 07/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume303,936 shs
Average Volume258,531 shs
Market Capitalization$423.61 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MGTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Magenta Therapeutics logo

About Magenta Therapeutics

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to bring the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. The company is developing C100 and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent prophylaxis of graft-versus-host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, evaluate potential utility of MGTA-117 for conditioning of patients receiving one or more investigational lentiviral gene therapies; and clinical trial collaboration with bluebird bio, Inc. to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.58 out of 5 stars

Medical Sector

909th out of 4,434 stocks

Pharmaceutical Preparations Industry

429th out of 1,734 stocks

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions

Is Magenta Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Magenta Therapeutics stock.
View analyst ratings for Magenta Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Magenta Therapeutics?

Wall Street analysts have given Magenta Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Magenta Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Magenta Therapeutics' next earnings date?

Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Magenta Therapeutics

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics, Inc. (NASDAQ:MGTA) issued its earnings results on Thursday, May, 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.03.
View Magenta Therapeutics' earnings history

How has Magenta Therapeutics' stock price been impacted by Coronavirus?

Magenta Therapeutics' stock was trading at $9.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MGTA shares have decreased by 21.0% and is now trading at $7.24.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MGTA?

6 equities research analysts have issued 1 year price objectives for Magenta Therapeutics' stock. Their forecasts range from $17.00 to $22.00. On average, they anticipate Magenta Therapeutics' share price to reach $19.60 in the next year. This suggests a possible upside of 170.7% from the stock's current price.
View analysts' price targets for Magenta Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Magenta Therapeutics' key executives?

Magenta Therapeutics' management team includes the following people:
  • Dr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 50, Pay $793.26k)
  • Mr. Stephen F. Mahoney, Chief Financial & Operating Officer and Treasurer (Age 50, Pay $420.48k)
  • Dr. John C. Davis Jr., M.D., M.P.H., M.S., Head of R&D and Chief Medical Officer (Age 59, Pay $608.63k)
  • Mr. David Wayne Nichols, Chief Technical Officer (Age 57)
  • Dr. Lisa M. Olson Ph.D., Head of Research & Chief Scientific Officer (Age 61)
  • Mr. Jim Haney, Sr. Director of Investor Relations
  • Mr. Thomas W. Beetham, Chief Legal Officer (Age 51)
  • Lyndsey Scull, Director of Corp. Communications
  • Ms. Kristen Stants, Chief People Officer (Age 48)
  • Ms. Catherine Monaghan, Head of Clinical Devel. Operations

What is Jason Gardner's approval rating as Magenta Therapeutics' CEO?

3 employees have rated Magenta Therapeutics CEO Jason Gardner on Jason Gardner has an approval rating of 60% among Magenta Therapeutics' employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Magenta Therapeutics' key competitors?

What other stocks do shareholders of Magenta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP).

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

How do I buy shares of Magenta Therapeutics?

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $7.24.

How much money does Magenta Therapeutics make?

Magenta Therapeutics has a market capitalization of $423.61 million. The company earns $-74,940,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does Magenta Therapeutics have?

Magenta Therapeutics employs 67 workers across the globe.

What is Magenta Therapeutics' official website?

The official website for Magenta Therapeutics is

Where are Magenta Therapeutics' headquarters?

Magenta Therapeutics is headquartered at 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.